Vasculitis induced by tumor necrosis factor-targeted therapies

Current Rheumatology Reports

Volumn 10, Issue 6, 2008, Pages 442-448

  Ramos Casals, Manuel ^a   Brito Zerón, Pilar ^b   Cuadrado, Maria Jose ^b   Khamashta, Munther A ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHYLPREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANAPHYLACTOID PURPURA; ANKYLOSING SPONDYLITIS; ARTERY DISEASE; AUTOIMMUNE DISEASE; BLISTER; BRONCHITIS; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL RETINA VEIN OCCLUSION; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL FEATURE; CONFUSION; CROHN DISEASE; CUTANEOUS VASCULITIS; DRUG RECHALLENGE; DRUG TARGETING; DRUG WITHDRAWAL; ERYTHEMA; FOCAL GLOMERULONEPHRITIS; FOLLOW UP; GALLBLADDER DISEASE; GLOMERULONEPHRITIS; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LEUKOCYTOCLASTIC VASCULITIS; LUNG HEMORRHAGE; LUNG NODULE; LUNG TOXICITY; LYMPHOCYTIC BRONCHITIS; LYMPHOCYTIC VASCULITIS; MEMBRANOUS GLOMERULONEPHRITIS; MONONEUROPATHY; MOTOR NEUROPATHY; NECROTIZING ARTERITIS; NEPHROTOXICITY; NEUROPATHY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; POLYARTERITIS NODOSA; PSORIATIC ARTHRITIS; PULMONARY VASCULITIS; PURPURA; RETREATMENT; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SEIZURE; SKIN DEFECT; SKIN ULCER; STROKE; SYSTEMIC VASCULITIS; TEMPORAL ARTERITIS; URTICARIA VASCULITIS; VASCULITIS; VISCERAL VASCULITIS; BLOOD VESSEL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; PATHOLOGY; PATHOPHYSIOLOGY;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; BLOOD VESSELS; HUMANS; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS;

EID: 58149375907     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-008-0072-z     Document Type: Review

References (54)

1. Haraoui B: Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum 2005, 34:7-11.
2. Nurmohamed MT, Dijkmans BA: Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 2005, 65:661-694.
3. Bongartz T, Sutton AJ, Sweeting MJ, et al.: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
4. Genovese MC, Bathon JM, Fleischmann RM, et al.: Long-term safety, efficacy and radiographic outcomes with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol 2005, 32:1232-1242.
5. Lebwohl M, Gottlieb A, Wallis W, Zitnik R: Safety and efficacy of over 7 years of etanercept therapy in a global population of patients with rheumatoid arthritis. J Am Acad Dermatol 2005, 52:195.
6. Haraoui B, Keystone E: Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr Opin Rheumatol 2006, 18:96-100.
7. Rubin RL: Drug-induced lupus. Toxicology 2005, 209:135-147.
8. Anandacoomarasamy A, Kannangara S, Barnsley L: Cutaneous vasculitis associated with infliximab in the treatment of rheumatoid arthritis. Intern Med J 2005, 35:638-640.
9. Ashok D, Dubey S, Tomlinson I: C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab. Clin Rheumatol 2008, 27:261-264.
10. Brion PH, Mittal-Henkle A, Kalunian KC: Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med 1999, 131:634.
11. Cocito D, Bergamasco B, Tavella A, et al.: Multifocal motor neuropathy during treatment with infliximab. J Peripher Nerv Syst 2005, 10:386-387.
12. Cunnane G, Warnock M, Fye KH, Daikh DI: Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum 2002, 47:445-449.
13. De Bandt M, Sibilia J, Le Loët X, et al.: Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: A French national survey. Arthritis Res Ther 2005, 7:R545-R551.
14. Doulton TW, Tucker B, Reardon J, Velasco N: Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis. Clin Nephrol 2004, 62:234-238.
15. Duffy TN, Genta M, Moll S, et al.: Henoch Schönlein purpura following etanercept treatment of rheumatoid arthritis. Clin Exp Rheumatol 2006, 24(2 Suppl 41):S106.
16. Flendrie M, Vissers WH, Creemers MC, et al.: Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005, 7:R666-R676.
17. Galaria NA, Werth VP, Schumacher HR: Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000, 27:2041-2044.
18. Goulão J, Cunha H, Anes I, et al.: Urticarial vasculitis due do infliximab. J Eur Acad Dermatol Venereol 2008, 22:882-883.
19. Jarand J, Zochodne DW, Martin LO, Voll C: Neurological complications of infliximab. J Rheumatol 2006, 33:1018-1020.
20. Jarrett SJ, Cunnane G, Conaghan PG, et al.: Anti-tumor necrosis factor-alpha therapy-induced vasculitis: Case series. J Rheumatol 2003, 30:2287-2291.
21. Juan A, Ribas B, Nadal C, Ros I: Treating leukocytoclastic vasculitis associated with etanercept therapy. Is it necessary to stop etanercept? J Rheumatol 2005, 32:2061.
22. Lebas D, Staumont-Sallé D, Solau-Gervais E, et al.: Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases [French]. Ann Dermatol Venereol 2007, 134:337-342.
23. Lee A, Kasama R, Evangelisto A, et al.: Henoch-Schonlein purpura after etanercept therapy for psoriasis. J Clin Rheumatol 2006, 12:249-251.
24. Leydet-Quilici H, Luc M, Armingeat T, et al.: Giant cell arteritis during adalimumab treatment for rheumatoid arthritis. Joint Bone Spine 2007, 74:303-304.
25. Martinez-Taboada VM, Val-Bernal JF, Pesquera LC, et al.: Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis. Scand J Rheumatol 2006, 35:322-323.
26. McCain ME, Quinet RJ, Davis WE: Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford) 2002, 41:116-117.
27. McIlwain L, Carter JD, Bin-Sagheer S, et al.: Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab. J Clin Gastroenterol 2003, 36:411-413.
28. Mohan N, Edwards ET, Cupps TR, et al.: Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 2004, 31:1955-1958.
29. Mor A, Bingham C 3rd, Barisoni L, et al.: Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol 2005, 32:740-743.
30. Orpin SD, Majmudar VB, Soon C, et al.: Adalimumab causing vasculitis. Br J Dermatol 2006, 154:998-999.
31. Richette P, Dieude P, Damiano J, et al.: Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. J Rheumatol 2004, 31:2079-2081.
32. Richez C, Blanco P, Lagueny A, et al.: Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. Neurology 2005, 64:1468-1470.
33. Rodriguez-Escalera C, Belzunegui J, Lopez-Dominguez L, et al.: Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy. Rheumatology (Oxford) 2005, 44:132-133.
34. Roux CH, Brocq O, Albert C, et al.: Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis. Joint Bone Spine 2004, 71:444-445.
35. Saint Marcoux B, De Bandt M, CRI (Club Rhumatismes et Inflammation): Vasculitides induced by TNFalpha antagonists: A study in 39 patients in France. Joint Bone Spine 2006, 73:710-713.
36. Seton M: Giant cell arteritis in a patient taking etanercept and methotrexate. J Rheumatol 2004, 31:1467.
37. Simms R, Kipgen D, Dahill S, et al.: ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy. Am J Kidney Dis 2008, 51:e11-e14.
38. Singer OC, Otto B, Steinmetz H, Ziemann U: Acute neuropathy with multiple conduction blocks after TNFalpha monoclonal antibody therapy. Neurology 2004, 63:1754.
39. Srivastava MD, Alexander F, Tuthill RJ: Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scand J Immunol 2005, 61:329-336.
40. Stokes MB, Foster K, Markowitz GS, et al.: Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005, 20:1400-1406.
41. Stübgen JP: Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 2008, 37:281-292.
42. Swale VJ, Perrett CM, Denton CP, et al.: Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol 2003, 28:604-607.
43. Tektonidou MG, Serelis J, Skopouli FN: Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment. Clin Rheumatol 2007, 26:258-260.
44. Wendling D, Streit G, Lehuede G, et al.: Cutaneous lymphocytic vasculitis during TNFalpha antagonist therapy for polyarthritis. Joint Bone Spine 2006, 73:215-216.
45. Maini RN, Breedveld FC, Kalden JR, et al.: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004, 50:1051-1065.
46. Kroesen S, Widmer AF, Tyndall A, Hasler P: Serious bacterial infections in patients with rheumatoid arthritis under anti- TNF-alpha therapy. Rheumatology 2003, 42:617-621.
47. Bieber J, Kavanaugh A: Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments. Rheum Dis Clin North Am 2004, 30:257-270.
48. Mohan N, Edwards ET, Cupps TR, et al.: Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001, 44:2862-2869.
49. Wolfe F, Michaud K: LymphomaTin rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004, 50:1740-1751.
50. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al.: Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases. Medicine 2007, 86:242-251.
51. Merkel PA: Drug-induced vasculitis. Rheum Dis Clin North Am 2001, 27:849-862.
52. Gonzalez-Gay MA, Garcia-Porrua C, Pujol RM: Clinical approach to cutaneous vasculitis. Curr Opin Rheumatol 2005, 17:56-61.
53. Ramos-Casals M, Nardi N, Lagrutta M, et al.: Vasculitis in systemic lupus erythematosus: Prevalence and clinical characteristics in 670 patients. Medicine 2006, 85:95-104.
54. Jennette JC, Falk RJ, Andrassy K, et al.: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994, 37:187-192.